Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015 DryLet, LLC ... in applications such as animal waste reduction, bioremediation, ... reduction in wastewater treatment plants and restaurant kitchen ... at the National Restaurant Association’s NRA Show 2015, ... Representatives of the company will be available to ...
(Date:4/24/2015)... -- Navitas Life Sciences is delighted to announce the appointment of ... Services. Shalabh is a proven leader in Life Science consulting ... as well as a Strategy consultant at Accenture. ... ... to welcome Shalabh into this critical role and also as ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 Athena San ... development of executive women in San Diego’s technology and ... 17th Annual Pinnacle Awards at their Gala on April ... Hotel. Register now at http://athenasd.org/events/ , The ... the Athena San Diego vision of fostering networking, risk ...
(Date:4/23/2015)... Six startups from Russia traveled to ... part of the U.S.-Russia Innovation Corridor (USRIC) program. ... startups to participate in the program since the ... University of Maryland (UMD) signed a Memorandum of ... in the biomedical industry in 2013. , Supported ...
Breaking Biology Technology:DryLet to Showcase Bio-React at the National Restaurant Association’s NRA Show 2015 May 16-19, 2015 in Chicago, Illinois 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4
... in Second Half 2008, ANNAPOLIS, Md., Aug. ... biodefense company developing medical countermeasures,against biological and chemical ... second quarter and six months ended June 30,2008. ... -- Submitted response to a Request for ...
... More than 35% Compared to the previous Quarter ... Production Reaches 200,000 OmniPods per Month, BEDFORD, Mass., Aug. ... patch pump technology with its OmniPod(R),Insulin Management System, today announced ... 30, 2008., Second quarter 2008 reported revenue increased 131% ...
... Biosciences continues to,expand its offering of IRDye ... IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye 800CW,Donkey ... and IRDye 800CW Goat,Anti-Rat IgG antibodies are ... for multiple applications including,quantitative Westerns, In-Cell Westerns, ...
Cached Biology Technology:PharmAthene Reports Second Quarter 2008 Financial and Operational Results 2PharmAthene Reports Second Quarter 2008 Financial and Operational Results 3PharmAthene Reports Second Quarter 2008 Financial and Operational Results 4PharmAthene Reports Second Quarter 2008 Financial and Operational Results 5PharmAthene Reports Second Quarter 2008 Financial and Operational Results 6PharmAthene Reports Second Quarter 2008 Financial and Operational Results 7PharmAthene Reports Second Quarter 2008 Financial and Operational Results 8Insulet Reports Second Quarter 2008 Results 2Insulet Reports Second Quarter 2008 Results 3Insulet Reports Second Quarter 2008 Results 4Insulet Reports Second Quarter 2008 Results 5Insulet Reports Second Quarter 2008 Results 6Insulet Reports Second Quarter 2008 Results 7Insulet Reports Second Quarter 2008 Results 8
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... unique Mayo Clinic collaboration has revived the healing wisdom ... extract described in a 17th century Dutch herbal text ... from the Atun tree effectively control bacteria that can ... circa 1650. He documented his traditional healing methods in ...
... and Hispanic patients and those who are uninsured are less ... been associated with better outcomes, according to a study in ... improve the quality of surgical care in the United States ... hospitals for certain procedures, since a number of studies have ...
... experiments of their kind, researchers at Rice University and ... have determined that carbon nanotubes injected directly into the ... health effects and circulate for more than one hour ... findings are from the first in vivo animal study ...
Cached Biology News:Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug 2Minorities, uninsured less likely to receive care at high-volume hospitals 2Pure carbon nanotubes pass first in vivo test 2
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... The economical ICS-90 uses continuous chemical ... to give you fast, accurate determinations of ... ranges. Easy to operate, quick to equilibrate, ... the compact ICS-90 helps you achieve maximum ...
... MATra-si Reagent optimized for siRNA applications, ... loaded with the nucleic acid of interest. ... dose is then rapidly drawn towards and ... efficient transfection. MATra-si Reagent can be used ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
Biology Products: